Alaunos faces Nasdaq delisting threat over failure to meet $2.5 million stockholders’ equity rule
Bitget2026/10/09 20:31Alaunos Therapeutics received a Nasdaq delisting notice on Oct. 5, 2026 for failing to meet the $2.5 million stockholders’ equity rule. The company plans to request a Nasdaq hearings panel review, which would pause any suspension or delisting at least until the hearing. It is evaluating strategic alternatives with a financial adviser to bolster its financial position and regain Nasdaq listing compliance. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alaunos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-419154), on October 09, 2026, and is solely responsible for the information contained therein.
- Alaunos Therapeutics received a Nasdaq delisting notice on Oct. 5, 2026 for failing to meet the $2.5 million stockholders’ equity rule.
- The company plans to request a Nasdaq hearings panel review, which would pause any suspension or delisting at least until the hearing.
- It is evaluating strategic alternatives with a financial adviser to bolster its financial position and regain Nasdaq listing compliance.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
United States Dollar Index remains subdued as lower oil prices ease inflation pressure
Silver Price Forecast: XAG/USD rises to near $53.00 as lower oil eases inflation pressure
Crypto prices
More
